A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection.
about
Recombinant human gamma interferon in human immunodeficiency virus-infected children: safety, CD4(+)-lymphocyte count, viral load, and neutrophil function (AIDS Clinical Trials Group Protocol 211)Effect of food on the bioavailability of stavudine in subjects with human immunodeficiency virus infection.Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian childrenSafety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children.Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapyPharmacokinetics of single-dose oral stavudine in subjects with renal impairment and in subjects requiring hemodialysis.Determination of dosing guidelines for stavudine (2',3'-didehydro-3'-deoxythymidine) in children with human immunodeficiency virus infectionPharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates.LIPODYSTROPHY SYNDROME IN HIV-INFECTED CHILDREN ON HAART.Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children.Quantitation of intracellular zidovudine phosphates by use of combined cartridge-radioimmunoassay methodology.Age-related differences in the pharmacokinetics of stavudine in 272 children from birth to 16 years: a population analysis.High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study.Antiretroviral bioanalysis methods of tissues and body biofluids.Estimation of intracellular concentration of stavudine triphosphate in HIV-infected children given a reduced dose of 0.5 milligrams per kilogram twice daily.
P2860
Q33637000-E90385A8-59D8-4DE7-AB74-35609D7CCED4Q33696676-285E89BC-56E5-4031-B184-2EFEF3B5F8EFQ33839338-C7B4EC1D-93CF-4030-9E3E-3FED3F4C9A5AQ33976456-97BB6226-6A55-4FC2-9964-B9A125E9A45FQ33979204-5245D1BC-9B8B-4018-A737-F0BDDCB849E3Q33980240-C884860F-AA6F-4D95-A292-174AA9C85569Q33981606-EEC7CC79-AFCA-429C-996C-73F321014525Q33983697-F039E6BD-B0D9-4CA5-9233-2BF988C5BC7EQ34058478-8631F80A-B53B-4B71-AF79-876A4159F209Q34544211-166220EF-C62D-48BB-9BF6-E5E9E301D4C3Q35129433-B4792C7E-5EE4-4B99-B2AF-126C1CA32817Q36024522-A54E5409-9F45-405B-ABC5-DB4B5E1E1567Q36646867-EBD4F74D-5BF4-49B8-AA72-8B3B664BFDBDQ37332868-07E78D0B-CB9C-4AB9-A4D6-AC165C1616FBQ37544710-9D993BEE-1DDA-4582-91A9-37BAECA68796
P2860
A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
A phase I/II evaluation of sta ...... unodeficiency virus infection.
@en
A phase I/II evaluation of stavudine
@nl
type
label
A phase I/II evaluation of sta ...... unodeficiency virus infection.
@en
A phase I/II evaluation of stavudine
@nl
prefLabel
A phase I/II evaluation of sta ...... unodeficiency virus infection.
@en
A phase I/II evaluation of stavudine
@nl
P2093
P1433
P1476
A phase I/II evaluation of sta ...... unodeficiency virus infection.
@en
P2093
Federici ME
Goldsmith JC
Schultze ME
P304
P407
P433
P577
1995-08-01T00:00:00Z